| 000 | 01717 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250517100115.0 | ||
| 264 | 0 | _c20170713 | |
| 008 | 201707s 0 0 eng d | ||
| 022 | _a1573-7241 | ||
| 024 | 7 |
_a10.1007/s10557-016-6666-1 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aRosenson, Robert S | |
| 245 | 0 | 0 |
_aEfficacy and Safety of the PCSK9 Inhibitor Evolocumab in Patients with Mixed Hyperlipidemia. _h[electronic resource] |
| 260 |
_bCardiovascular drugs and therapy _c06 2016 |
||
| 300 |
_a305-13 p. _bdigital |
||
| 500 | _aPublication Type: Clinical Trial, Phase II; Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial | ||
| 650 | 0 | 4 | _aAdolescent |
| 650 | 0 | 4 | _aAdult |
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 | _aAged, 80 and over |
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadverse effects |
| 650 | 0 | 4 | _aAntibodies, Monoclonal, Humanized |
| 650 | 0 | 4 |
_aAnticholesteremic Agents _xadverse effects |
| 650 | 0 | 4 |
_aApolipoproteins B _xblood |
| 650 | 0 | 4 |
_aCholesterol _xblood |
| 650 | 0 | 4 | _aDouble-Blind Method |
| 650 | 0 | 4 |
_aEzetimibe _xadverse effects |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aHypercholesterolemia _xblood |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aMiddle Aged |
| 650 | 0 | 4 | _aPCSK9 Inhibitors |
| 650 | 0 | 4 | _aTreatment Outcome |
| 650 | 0 | 4 |
_aTriglycerides _xblood |
| 650 | 0 | 4 | _aYoung Adult |
| 700 | 1 | _aJacobson, Terry A | |
| 700 | 1 | _aPreiss, David | |
| 700 | 1 | _aDjedjos, C Stephen | |
| 700 | 1 | _aDent, Ricardo | |
| 700 | 1 | _aBridges, Ian | |
| 700 | 1 | _aMiller, Michael | |
| 773 | 0 |
_tCardiovascular drugs and therapy _gvol. 30 _gno. 3 _gp. 305-13 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s10557-016-6666-1 _zAvailable from publisher's website |
| 999 |
_c26072942 _d26072942 |
||